In the phase III PADA-1 trial presented at 2021 San Antonio Breast Cancer Symposium, it was observed that switching from an aromatase inhibitor plus palbociclib to fulvestrant and palbociclib upon early identification of the ESR1 mutation in plasma-before disease progression- the median PFS was doubled. The gene discussed is CYP19A1; the disease is breast cancer.